Terns Pharmaceuticals Inc (TERN) - Total Liabilities
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has total liabilities worth $17.59 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TERN net asset momentum to track the company's year-over-year net asset growth rate.
Terns Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Terns Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NIP Group Inc. American Depositary Shares
NASDAQ:NIPG
|
USA | $73.10 Million |
|
Veracruz Properties SOCIMI SA
MC:YVCP
|
Spain | €41.37 Million |
|
Peninsula Energy Ltd
AU:PEN
|
Australia | AU$44.01 Million |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
Thailand | ฿4.32 Billion |
|
Solborn Inc
KQ:035610
|
Korea | ₩51.71 Billion |
|
Talga Group Ltd
F:TGX
|
Germany | €5.87 Million |
|
AXON PARTNERS GRP EO -10
F:XE1
|
Germany | €8.31 Million |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩109.40 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Terns Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Terns Pharmaceuticals Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Terns Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Terns Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.06 Million | +37.33% |
| 2023-12-31 | $13.15 Million | +30.42% |
| 2022-12-31 | $10.08 Million | +29.82% |
| 2021-12-31 | $7.77 Million | -67.23% |
| 2020-12-31 | $23.70 Million | +324.70% |
| 2019-12-31 | $5.58 Million | -66.87% |
| 2018-12-31 | $16.84 Million | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more